期刊文献+

LC-MS/MS测定尿样瑞舒伐他汀浓度及人体药动学研究 被引量:3

Determination of Rosuvastatin in Urine by HPLC-MS/MS Assay and Study on Its Pharmacokinetics in Healthy Subjects
下载PDF
导出
摘要 目的 建立HPLC-MS/MS法测定尿样中的瑞舒伐他汀浓度,研究其在健康国人体内的药动学特征。方法 选择匹伐他汀为内标,尿样经叔丁基甲醚提取,采用GL Nuclosil C18(2mm×50mm,5μm),以甲醇-水-甲酸(70∶30∶1)为流动相,流速0.25mL·min^-1;质谱检测为正离子方式下的MRM扫描。24例健康男性受试者随机等分为3组,分别每日空腹口服瑞舒伐他汀5,10和20mg,连续7d,测定药后不同时间段的尿药浓度。结果 瑞舒伐他汀的线性范围为2-500μg·L^-1(r=0.9998),最低检测质量浓度为2μg·L^-1,提取回收率〉75%,日内和日间RSD均≤11.4%。受试者服药后的最大排泄速率均出现在药后5h左右,消除半衰期t1/2为11.2-15.8h,累积排泄率为10%,比白种人高约2倍。结论 在本研究剂量范围内,瑞舒伐他汀呈线性动力学特征,中国人与白种人的药动学特征存在明显的种族差异。 OBJECTIVE To establish a HPLC-MS/MS method for the determination of rosuvastatin in urine and to investigate its pharmacokinetic characteristics in healthy Chinese subjects. METHODS Rosuvastatin and pitavastatin (IS) were extracted from urine with methyl-tert butyl ether and then separated on a GL Nuclosil C18 column ,using methanol-water-formic acid (70: 30:1 ) as the mobile phase at a flow rate of 0. 25 mL·min^-1. The mass spectrometer was operated with positive electrospray ionization, and quantitation was performed using multiple reaction monitoring (MRM) mode. 24 Subjects were administered randomly with 5,10 or 20 mg rosuvastatin oral dose daily for 7 d. The urine concentrations of rosuvastatin were determined by HPLC-MS/MS method. RESULTS The linear range was 2 -500 μg·L^-1 (r =0. 999 8) with a lower limit of quantitation of 2μg·L^-1. The intra- and inter-day precision were below 11.4% and the extraction recovery was above 75%. The maximum observed excretion of rosuvastatin appeared at 5 h and the elimination half-life was about 11.2 - 15. 8 h. Approximately 10% of the close was recovered in urine,which was much higher (2-fold) than that of Caucasian. CONCLUSION Rosuvastatin exhibited linear pharmacokinetic characteristics over the studied dose range. It had been shown that there was remarkable ethnic difference in pharmacokinetic profiles between Chinese and Caucasian.
出处 《中国药学杂志》 CAS CSCD 北大核心 2007年第15期1174-1177,共4页 Chinese Pharmaceutical Journal
基金 863国家攻关项目(2002AA2Z341A 2004AA2Z3760)
关键词 瑞舒伐他汀 药动学 高效液相色谱-串联质谱 种族差异 rosuvastatin pharmacokinetics HPLC-MS/MS ethnic difference
  • 相关文献

参考文献7

  • 1BROWN W V,BAYS H E,HASSMAN D R,et al.Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia:A randomized,double-blind,52-week trial[J].Am Heart J,2002,144:1036-1043.
  • 2HULL C K,PENMAN A D,SMITH C K,et al.Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection[J].J Chromatogr B Analyt Technol Biomed Life Sci,2002,772(2):219-228.
  • 3OUDHOFF K A,SANGSTER T,THOMAS E,et al.Application of microbore HPLC in combination with tandem MS for the quantification of rosuvastatin in human plasma[J].J Chromatogr B Analyt Technol Biomed Life Sci,2006,832(2):191-196.
  • 4HULL C K,MARTIN P D,WARWICK M J,et al.Quantification of the N-desmethyl metabolite of rosuvastatin in human plasma by automated SPE followed by HPLC with tandem MS detection[J].J Pharm Biomed Anal,2004,35 (3):609-614.
  • 5LEE E,RYAN S,BIRMINGHAM B,et al.Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment[J].Clin Pharmacol Ther,2005,78(4):330-341.
  • 6MARTIN P D,WARWICK M J,DANE A L,et al.A doubleblind,randomized,incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers[J].Clin Ther,2003,25 (8):2215-2224.
  • 7MARTIN P D,WARWICK M J,DANE A L,et al.Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers[J].Clin Ther,2003,25(10):2553-2563.

同被引文献34

  • 1The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.第二次中国临床血脂控制达标率及影响因素多中心协作研究[J].中华心血管病杂志,2007,35(5):420-427. 被引量:126
  • 2Arca M,Gaspardone A.Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events[J].Drugs,2007,67(Suppl 1):29-42.
  • 3Liao JK.Safety and efficacy of statins in Asians[J].Am J Cardiol FEB,2007,99(3):410-413.
  • 4Lee E,Ryan S,Birmingham B,et al.Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment[J].Clin Pharmacol Ther,2005,78(4):330-341.
  • 5Chiang CE,Huang SS,Sung SH.Efficacy and safety of rosuvastatin in Taiwan Residents patients[J].J Chin Med Assoc,2008,71(3):113-118.
  • 6Koba S,Sasaki J.Treatment of hyperlipidemia from Japanese evidence[J].J Atheroscler Thromb,2006,13(6):267-280.
  • 7Sakamoto T,Ogawa H."Just make it lower" is an alternative strategy of lipid-lowering therapy with statins in Japanese patients:LDL-cholesterol:the lower,the better; is it true for Asians?(Con)[J].Circ J,2010,74(8):1731-1741.
  • 8Miyauchi K,Daida H.Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease:LDL-cholesterol:the lower,the better; is it true for Asians?(Pro)[J].Circ J,2010,74(8):1718-1730.
  • 9Garmendia F,Brown AS,Reiber I,et al.Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease(the GOALLS study)[J].Curr Med Res Opin,2000,16(3):208-219.
  • 10Chung N,Cho SY,Choi DH,et al.STATT:a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease.Simvastatin Treats Asians to Target[J].Clin Ther,2001,23(6):858-870.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部